Brandon Kovarovic

Brandon Kovarovic

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2018 in Expert Review of Medical Devices
Verified
Journal Article
Closed access
OROren M. Rotman
Oren M. Rotman
MBMatteo Bianchi
Matteo Bianchi
RGRam P. Ghosh
Ram P. Ghosh
BKBrandon Kovarovic
Brandon Kovarovic
DBDanny Bluestein
Danny Bluestein
Transcatheter aortic valve replacement (TAVR) has emerged as an effective minimally-invasive alternative to surgical valve replacement in medium- to high-risk, elderly patients with calcific aortic valve disease and severe aortic stenosis. The rapid growth of the TAVR devices market has led to a high variety of designs, each aiming to address persistent complications associated with TAVR valves that may hamper the anticipated expansion of TAVR utility. Here we outline the challenges and the technical demands that TAVR devices need to address for achieving the desired expansion, and review design aspects of selected, latest generation, TAVR valves of both clinically-used and investigational devices. We further review in detail some of the up-to-date modeling and testing approaches for TAVR, both computationally and experimentally, and additionally discuss those as complementary approaches to the ISO 5840-3 standard. A comprehensive survey of the prior and up-to-date literature was conducted to cover the most pertaining issues and challenges that TAVR technology faces. The expansion of TAVR over SAVR and to new indications seems more promising than ever. With new challenges to come, new TAV design approaches, and materials used, are expected to emerge, and novel testing/modeling methods to be developed.

7 September 2018 in Annals of Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
OROren M. Rotman
Oren M. Rotman
BKBrandon Kovarovic
Brandon Kovarovic
WCWei-Che Chiu
Wei-Che Chiu
MBMatteo Bianchi
Matteo Bianchi
GMGil Marom
Gil Marom
Danny BluesteinDanny Bluestein
Danny Bluestein

1 February 2020 in ASAIO Journal
Verified
Journal Article
Closed access
OROren M. Rotman
Oren M. Rotman
BKBrandon Kovarovic
Brandon Kovarovic
MBMatteo Bianchi
Matteo Bianchi
MSMarvin J. Slepian
Marvin J. Slepian
Danny BluesteinDanny Bluestein
Danny Bluestein
Transcatheter aortic valve replacement (TAVR) has emerged as an effective therapy for the unmet clinical need of inoperable patients with severe aortic stenosis (AS). Current clinically used tissue TAVR valves suffer from limited durability that hampers TAVR’s rapid expansion to younger, lower risk patients. Polymeric TAVR valves optimized for hemodynamic performance, hemocompatibility, extended durability, and resistance to calcific degeneration offer a viable solution to this challenge. We present extensive in vitro durability and stability testing of a novel polymeric TAVR valve (PolyNova valve) using 1) accelerated wear testing (AWT, ISO 5840); 2) calcification susceptibility (in the AWT)—compared with clinically used tissue valves; and 3) extended crimping stability (valves crimped to 16 Fr for 8 days). Hydrodynamic testing was performed every 50M cycles. The valves were also evaluated visually for structural integrity and by scanning electron microscopy for evaluation of surface damage in the micro-scale. Calcium and phosphorus deposition was evaluated using micro-computed tomography (μCT) and inductive coupled plasma spectroscopy. The valves passed 400M cycles in the AWT without failure. The effective orifice area kept stable at 1.8 cm2 with a desired gradual decrease in transvalvular pressure gradient and regurgitation (10.4 mm Hg and 6.9%, respectively). Calcium and phosphorus deposition was significantly lower in the polymeric valve: down by a factor of 85 and 16, respectively—as compared to a tissue valve. Following the extended crimping testing, no tears nor surface damage were evident. The results of this study demonstrate the potential of a polymeric TAVR valve to be a viable alternative to tissue-based TAVR valves.

25 October 2023 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Closed access
KBKyle Baylous
Kyle Baylous
RHRyan Helbock
Ryan Helbock
BKBrandon Kovarovic
Brandon Kovarovic
SASalwa Anam
Salwa Anam
MSMarvin Slepian
Marvin Slepian
Danny BluesteinDanny Bluestein
Danny Bluestein

7 February 2022 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
SRSymon Reza
Symon Reza
MBMatteo Bianchi
Matteo Bianchi
BKBrandon Kovarovic
Brandon Kovarovic
SASalwa Anam
Salwa Anam
Marvin SlepianMarvin Slepian
Marvin Slepian
Danny BluesteinDanny Bluestein
Danny Bluestein

6 April 2022 in Journal of Biomechanical Engineering
Verified
Journal Article
Closed access
PDF file
BKBrandon Kovarovic
Brandon Kovarovic
RHRyan Helbock
Ryan Helbock
KBKyle Baylous
Kyle Baylous
OROren M. Rotman
Oren M. Rotman
Marvin SlepianMarvin Slepian
Marvin Slepian
Danny BluesteinDanny Bluestein
Danny Bluestein
Tissue-based transcatheter aortic valve (AV) replacement (TAVR) devices have been a breakthrough approach for treating aortic valve stenosis. However, with the expansion of TAVR to younger and lower risk patients, issues of long-term durability and thrombosis persist. Recent advances in polymeric valve technology facilitate designing more durable valves with minimal in vivo adverse reactions. We introduce our second-generation polymeric transcatheter aortic valve (TAV) device, designed and optimized to address these issues. We present the optimization process of the device, wherein each aspect of device deployment and functionality was optimized for performance, including unique considerations of polymeric technologies for reducing the volume of the polymer material for lower crimped delivery profiles. The stent frame was optimized to generate larger radial forces with lower material volumes, securing robust deployment and anchoring. The leaflet shape, combined with varying leaflets thickness, was optimized for reducing the flexural cyclic stresses and the valve's hydrodynamics. Our first-generation polymeric device already demonstrated that its hydrodynamic performance meets and exceeds tissue devices for both ISO standard and patient-specific in vitro scenarios. The valve already reached 900 × 106 cycles of accelerated durability testing, equivalent to over 20 years in a patient. The optimization framework and technology led to the second generation of polymeric TAV design- currently undergoing in vitro hydrodynamic testing and following in vivo animal trials. As TAVR use is rapidly expanding, our rigorous bio-engineering optimization methodology and advanced polymer technology serve to establish polymeric TAV technology as a viable alternative to the challenges facing existing tissue-based TAV technology.